Personalized and Precision Medicine Journal
Where Innovations Meets Personalized and Precision Medicine

An Update on Kidney Diseases and Cancer

Document Type : Review Article

Author

Zahra Taheri

Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

https://doi.org/10.22034/pmj.2024.2030994.1038
Abstract
Lots of people are struggling with Kidney disease or cancer around the world. Chronic kidney disease (CKD) and renal cell carcinoma (RCC) are associated directionally and share risk factors. Because of the role of kidneys in detoxification, studying the relationship between cancer chemotherapy and kidney disorders is significant. This investigation fills the current gap between cancer occurrence and kidney problems.
CKD can induce RCC through a cystic disorder or oxidative stress. RCC also promotes CKD due to the tumor interactions, physical removal of kidney mass, and perioperative acute renal disease. Kidney failure also leads to renal cancer-specific pathways. For example, renal progenitors are converted to tumor-initiating cells through HIF, Notch, mTOR, and Hippo pathways. Furthermore, progress in cancer treatment during recent years has increased the overall survival of patients with advanced malignancies faced with early and late adverse effects from therapeutics. There are conflicting findings about the dosing of typical chemotherapeutics because of loss of kidney function. Recommended doses are usually according to expert opinion, not scientific evidence. This investigation has evaluated issues in cancer patients with kidney problems that can help patients by informing physicians about GFR loss and its effect on chemotherapy.
Keywords: kidney diseases, cancer, chemotherapy, CKD, AKI

Keywords

kidney diseases
cancer
chemotherapy
CKD
AKI

Subjects

  1. Lee M, Wang Q, Wanchoo R, Eswarappa M, Deshpande P, Sise ME. Chronic Kidney Disease in Cancer Survivors. Advances in Chronic Kidney Disease. 2021;28(5):469-76.e1.
  2. Carriazo S, Vanessa Perez-Gomez M, Ortiz A. Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology. Oxford University Press; 2020. p. 504-9.
  3. Mulay SR, Linkermann A, Anders H-J. Necroinflammation in kidney disease. Journal of the American Society of Nephrology: JASN. 2016;27(1):27.
  4. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. The Lancet. 2017;389(10075):1238-52.
  5. Peired AJ, Lazzeri E, Guzzi F, Anders H-J, Romagnani P. From kidney injury to kidney cancer. Kidney International. 2021;100(1):55-66.
  6. Young MD, Mitchell TJ, Vieira Braga FA, Tran MG, Stewart BJ, Ferdinand JR, et al. Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science. 2018;361(6402):594-9.
  7. Lazzeri E, Angelotti ML, Peired A, Conte C, Marschner JA, Maggi L, et al. Endocycle-related tubular cell hypertrophy and progenitor proliferation recover renal function after acute kidney injury. Nature communications. 2018;9(1):1344.
  8. Lasagni L, Angelotti ML, Ronconi E, Lombardi D, Nardi S, Peired A, et al. Podocyte regeneration driven by renal progenitors determines glomerular disease remission and can be pharmacologically enhanced. Stem cell reports. 2015;5(2):248-63.
  9. Kusaba T, Lalli M, Kramann R, Kobayashi A, Humphreys BD. Differentiated kidney epithelial cells repair injured proximal tubule. Proceedings of the National Academy of Sciences. 2014;111(4):1527-32.
  10. Kang HM, Huang S, Reidy K, Han SH, Chinga F, Susztak K. Sox9-positive progenitor cells play a key role in renal tubule epithelial regeneration in mice. Cell reports. 2016;14(4):861-71.
  11. Lindgren D, Boström A-K, Nilsson K, Hansson J, Sjölund J, Möller C, et al. Isolation and characterization of progenitor-like cells from human renal proximal tubules. The American journal of pathology. 2011;178(2):828-37.
  12. Peired AJ, Antonelli G, Angelotti ML, Allinovi M, Guzzi F, Sisti A, et al. Acute kidney injury promotes development of papillary renal cell adenoma and carcinoma from renal progenitor cells. Science translational medicine. 2020;12(536):eaaw6003.
  13. Christensen BM, Kim Y-H, Kwon T-H, Nielsen S. Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. American Journal of Physiology-Renal Physiology. 2006;291(1):F39-F48.
  14. Dey S, Hamilton Z, Noyes SL, Tobert CM, Keeley J, Derweesh IH, et al. Chronic kidney disease is more common in locally advanced renal cell carcinoma. Urology. 2017;105:101-7.
  15. O’Donnell K, Tourojman M, Tobert CM, Kirmiz SW, Riedinger CB, Demirjian S, et al. Proteinuria is a predictor of renal functional decline in patients with kidney cancer. The Journal of Urology. 2016;196(3):658-63.
  16. Shu S, Wang Y, Zheng M, Liu Z, Cai J, Tang C, et al. Hypoxia and hypoxia-inducible factors in kidney injury and repair. Cells. 2019;8(3):207.
  17. Chappell JC, Payne LB, Rathmell WK. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. The Journal of clinical investigation. 2019;129(2):442-51.
  18. Anders H-J, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nature Reviews Nephrology. 2018;14(6):361-77.
  19. Guo H, German P, Bai S, Barnes S, Guo W, Qi X, et al. The PI3K/AKT pathway and renal cell carcinoma. Journal of genetics and genomics. 2015;42(7):343-53.
  20. Charnley M, Ludford-Menting M, Pham K, Russell SM. A new role for Notch in the control of polarity and asymmetric cell division of developing T cells. Journal of Cell Science. 2020;133(5):jcs235358.
  21. Lasagni L, Ballerini L, Angelotti ML, Parente E, Sagrinati C, Mazzinghi B, et al. Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem cells. 2010;28(9):1674-85.
  22. Seeger-Nukpezah T, Geynisman DM, Nikonova AS, Benzing T, Golemis EA. The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. Nature Reviews Nephrology. 2015;11(9):515-34.
  23. Anorga S, Overstreet JM, Falke LL, Tang J, Goldschmeding RG, Higgins PJ, et al. Deregulation of Hippo–TAZ pathway during renal injury confers a fibrotic maladaptive phenotype. The FASEB Journal. 2018;32(5):2644.
  24. Xie J, Wang X, Proud CG. mTOR inhibitors in cancer therapy. F1000Research. 2016;5.
  25. Matsuura K, Nakada C, Mashio M, Narimatsu T, Yoshimoto T, Tanigawa M, et al. Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma. BMC cancer. 2011;11(1):1-10.
  26. Lee S, Karas PJ, Hadley CC, Bayley V JC, Khan AB, Jalali A, et al. The role of merlin/NF2 loss in meningioma biology. Cancers. 2019;11(11):1633.
  27. Boffetta P, Fontana L, Stewart P, Zaridze D, Szeszenia-Dabrowska N, Janout V, et al. Occupational exposure to arsenic, cadmium, chromium, lead and nickel, and renal cell carcinoma: a case–control study from Central and Eastern Europe. Occupational and environmental medicine. 2011;68(10):723-8.
  28. Akatsuka S, Yamashita Y, Ohara H, Liu Y-T, Izumiya M, Abe K, et al. Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. 2012.
  29. Ebert T, Pawelzik S-C, Witasp A, Arefin S, Hobson S, Kublickiene K, et al. Inflammation and premature ageing in chronic kidney disease. Toxins. 2020;12(4):227.
  30. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clinical journal of the American Society of Nephrology: CJASN. 2012;7(12):1938.
  31. Ishigami J, Grams ME, Chang AR, Carrero JJ, Coresh J, Matsushita K. CKD and risk for hospitalization with infection: the atherosclerosis risk in communities (ARIC) study. American Journal of Kidney Diseases. 2017;69(6):752-61.
  32. Hu M, Wang Q, Liu B, Ma Q, Zhang T, Huang T, et al. Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms. Frontiers in Cell and Developmental Biology. 2022;10:868715-.
  33. Putri AY, Thaha M. Role of oxidative stress on chronic kidney disease progression. Acta Medica Indonesiana. 2014;46(3):244-52.
  34. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. American Journal of Kidney Diseases. 2006;48(5):752-60.
  35. Shaw P, Chattopadhyay A. Nrf2–ARE signaling in cellular protection: Mechanism of action and the regulatory mechanisms. Journal of Cellular Physiology. 2020;235(4):3119-30.
  36. Tu W, Wang H, Li S, Liu Q, Sha H. The anti-inflammatory and anti-oxidant mechanisms of the Keap1/Nrf2/ARE signaling pathway in chronic diseases. Aging and disease. 2019;10(3):637.
  37. Feng Y-L, Chen H, Chen D-Q, Vaziri ND, Su W, Ma S-X, et al. Activated NF-κB/Nrf2 and Wnt/β-catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2019;1865(9):2317-32.
  38. Giri DK, Aggarwal BB. Constitutive activation of NF-κB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells: autocrine role of tumor necrosis factor and reactive oxygen intermediates. Journal of Biological Chemistry. 1998;273(22):14008-14.
  39. Helena JM, Joubert AM, Grobbelaar S, Nolte EM, Nel M, Pepper MS, et al. Deoxyribonucleic acid damage and repair: Capitalizing on our understanding of the mechanisms of maintaining genomic integrity for therapeutic purposes. International Journal of Molecular Sciences. 2018;19(4):1148.
  40. Buemi M, Floccari F, Costa C, Caccamo C, Belghity N, Campo S, et al. Dialysis-Related Genotoxicity: Sister Chromatid Exchanges and DNA Lesions in T and B Lymphocytes of Uremic Patients. Genomic Damage in Patients on Hemodiafiltration: Genomic Damage in Patients on Hemodiafiltration. Blood purification. 2006;24(5-6):569-74.
  41. Trabulus S, Guven GS, Altiparmak MR, Batar B, Tun O, Yalin AS, et al. DNA repair XRCC1 Arg399Gln polymorphism is associated with the risk of development of end-stage renal disease. Molecular biology reports. 2012;39:6995-7001.
  42. Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clinical journal of the American Society of Nephrology: CJASN. 2018;13(6):952.
  43. Quarles LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Experimental cell research. 2012;318(9):1040-8.
  44. Erben RG. Physiological actions of fibroblast growth factor-23. Frontiers in endocrinology. 2018:267.
  45. Lee EK, Martinez MCR, Blakely K, Santos KD, Hoang VC, Chow A, et al. FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia? Medical hypotheses. 2014;83(4):482-7.
  46. Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LC, Hudson MM, Skinner R, et al. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. The Lancet Oncology. 2019;20(1):e29-e41.
  47. Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. New England Journal of Medicine. 2015;373(26):2499-511.
  48. Lee M, Wang Q, Wanchoo R, Eswarappa M, Deshpande P, Sise ME. Chronic kidney disease in cancer survivors. Advances in Chronic Kidney Disease. 2021;28(5):469-76. e1.
  49. Ellis MJ, Parikh CR, Inrig JK, Kambay M, Patel UD. Chronic kidney disease after hematopoietic cell transplantation: a systematic review. American Journal of Transplantation. 2008;8(11):2378-90.
  50. Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clinical Journal of the American Society of Nephrology: CJASN. 2019;14(12):1692.
  51. Seethapathy H, Zhao S, Strohbehn IA, Lee M, Chute DF, Bates H, et al. Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors. Kidney international reports. 2020;5(10):1700-5.
  52. Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. Journal for immunotherapy of cancer. 2019;7(1):1-13.
  53. Ishii T, Fujimaru T, Nakano E, Takahashi O, Nakayama M, Yamauchi T, et al. Association between chronic kidney disease and mortality in stage IV cancer. International Journal of Clinical Oncology. 2020;25(9):1587-95. [DOI: 10.1007/s10147-020-01715-9].
  54. Maltoni M, Scarpi E, Pittureri C, Martini F, Montanari L, Amaducci E, et al. Prospective comparison of prognostic scores in palliative care cancer populations. The oncologist. 2012;17(3):446-54.
  55. Jang RW, Caraiscos VB, Swami N, Banerjee S, Mak E, Kaya E, et al. Simple prognostic model for patients with advanced cancer based on performance status. Journal of oncology practice. 2014;10(5):e335-e41.
  56. Shlipak MG, Stehman-Breen C, Fried LF, Song X, Siscovick D, Fried LP, et al. The presence of frailty in elderly persons with chronic renal insufficiency. American journal of kidney diseases. 2004;43(5):861-7.
  57. Caires-Lima R, Cayres K, Protásio B, Caires I, Andrade J, Rocha L, et al. Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1. Ecancermedicalscience. 2018;12.
  58. Wei Y-F, Chen J-Y, Lee H-S, Wu J-T, Hsu C-K, Hsu Y-C. Association of chronic kidney disease with mortality risk in patients with lung cancer: a nationwide Taiwan population-based cohort study. BMJ open. 2018;8(1):e019661.
  59. Launay-Vacher V, Spano J-P, Janus N, Gligorov J, Ray-Coquard I, Oudard S, et al. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Critical reviews in oncology/hematology. 2009;70(2):124-33.
  60. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376-84.
  61. Launay-Vacher V, Aapro M, De Castro Jr G, Cohen E, Deray G, Dooley M, et al. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Annals of Oncology. 2015;26(8):1677-84.
  62. Kitchlu A, Shapiro J, Amir E, Garg AX, Kim SJ, Wald R, et al. Representation of patients with chronic kidney disease in trials of cancer therapy. Jama. 2018;319(23):2437-9.
  63. Zhang Y, Zhang L, Abraham S, Apparaju S, Wu TC, Strong J, et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clinical Pharmacology & Therapeutics. 2009;85(3):305-11.
  64. Sprangers B, Jhaveri KD, Perazella MA. Improving cancer care for patients with chronic kidney disease. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2020;38(3):188-92.
  65. Latcha S. Pharmacokinetics of chemotherapeutic agents in kidney disease. Onco‐nephrology curriculum. 2016:1-9.
  66. Motwani SS, McMahon GM, Humphreys BD, Partridge AH, Waikar SS, Curhan GC. Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. Journal of Clinical Oncology. 2018;36(7):682.
  67. Asai A, Katsuno T, Yamaguchi M, Iwagaitsu S, Nobata H, Kinashi H, et al. Carboplatin-related acute interstitial nephritis in a patient with pancreatic neuroendocrine tumor. CEN case reports. 2020;9:114-21.
  68. Watanabe R, Takiguchi Y, Moriya T, Oda S, Kurosu K, Tanabe N, et al. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. British journal of cancer. 2003;88(1):25-30.
  69. Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Annals of Oncology. 2010;21(7):1395-403.
  70. Inoue A, Saijo Y, Kikuchi T, Gomi K, Suzuki T, Maemondo M, et al. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Annals of oncology. 2004;15(1):51-4.
  71. Veal GJ, English MW, Grundy RG, Shakespeare C, Glaser A, Waters F, et al. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Cancer chemotherapy and pharmacology. 2004;54:295-300.
  72. Guddati AK, Joy PS, Marak CP. Dose adjustment of carboplatin in patients on peritoneal dialysis. Medical oncology (Northwood, London, England). 2014;31(5):946. [DOI: 10.1007/s12032-014-0946-z].
  73. Ensergueix G, Pallet N, Joly D, Levi C, Chauvet S, Trivin C, et al. Ifosfamide nephrotoxicity in adult patients. Clinical kidney journal. 2020;13(4):660-5.
  74. Kaijser G, Beijnen J, Bult A, Underberg W. Ifosfamide metabolism and pharmacokinetics. Anticancer research. 1994;14(2A):517-31.
  75. Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, et al. Ifosfamide‐induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatric blood & cancer. 2007;48(4):447-52.
  76. Skinner R, Cotterill S, Stevens M. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. British journal of cancer. 2000;82(10):1636-45.
  77. Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, et al. Long-term evaluation of Ifosfamide-related nephrotoxicity in children. Journal of clinical oncology. 2009;27(32):5350-5.
  78. Farry JK, Flombaum CD, Latcha S. Long term renal toxicity of ifosfamide in adult patients–5 year data. European Journal of Cancer. 2012;48(9):1326-31.
  79. Kumar N, Shirali AC, editors. What is the best therapy for toxicity in the setting of methotrexate-associated acute kidney injury: high-flux hemodialysis or carboxypeptidase G2? Seminars in dialysis; 2014.
  80. Jhaveri KD, Flombaum C, Shah M, Latcha S. A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR< 30 mL/min) and end stage renal disease on hemodialysis. Journal of Oncology Pharmacy Practice. 2012;18(1):140-7.
  81. Van Warmerdam L, Rodenhuis S, ten Bokkel Huinink W, Maes Rt, Beijnen J. The use of the Calvert formula to determine the optimal carboplatin dosage. Journal of cancer research and clinical oncology. 1995;121:478-86.
  82. Shepherd ST, Gillen G, Morrison P, Forte C, Macpherson IR, White JD, et al. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. European Journal of Cancer. 2014;50(5):944-52.
  83. Mazloom AL. Tolerability of Carboplatin When Using Rounded Serum Creatinine Values. 2012.
  84. Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
  85. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clinical journal of the American Society of Nephrology: CJASN. 2010;5(6):1003.
  86. Levey AS, Coresh J, Greene T, Stevens LA, Zhang Y, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Annals of internal medicine. 2006;145(4):247-54.
  87. Rhee J, Kwon JM, Han SH, Kim SH, Park CH, Jeon JH, et al. Cockcroft-Gault, Modification of Diet in Renal Disease, and Chronic Kidney Disease Epidemiology Collaboration equations for estimating glomerular filtration rates in cancer patients receiving cisplatin-based chemotherapy. Kidney Research and Clinical Practice. 2017;36(4):342.
  88. Séronie-Vivien S, Toullec S, Malard L, Thomas F, Durrand V, Chatelut E. Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients. Medical Oncology. 2006;23:63-73.
  89. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro III AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Annals of internal medicine. 2009;150(9):604-12.
Personalized and Precision Medicine Journal
Volume 9, Issue 34
Original article
Summer 2024
Pages 35-44

  • Receive Date 27 April 2024
  • Revise Date 19 June 2024
  • Accept Date 13 August 2024

Home

Publication Ethics

Guide for Authors

Submit Manuscript

Contact Us